Post-EV + Pembrolizumab Progression in Urothelial Carcinoma: Choosing the Next Treatment

Authored by Natalia Gandur, published on 2026-05-11 18:14:54.0

This algorithm is designed for one focused clinical problem: selecting the next systemic therapy for patients with locally advanced unresectable or metastatic urothelial carcinoma whose disease has progressed after first-line enfortumab vedotin plus pembrolizumab. EV + pembrolizumab is now the preferred first-line standard in major guidelines, but there is still no universally accepted post-EV/pembrolizumab standard; publicly accessible guideline and review sources converge on a practical framework centered on platinum chemotherapy for platinum-naïve and fit patients, biomarker-directed therapy for selected tumors, and early clinical-trial referral.

  1. Patient with locally advanced unresectable or metastatic urothelial carcinoma with progression after first-line ENFORTUMAB VEDOTIN + PEMBROLIZUMAB
    • CONFIRM PROGRESSION & REASSESS
      Radiographic, clinical or symptomatic progression Review prior systemic and perioperative therapy Assess current ECOG/PS, frailty, organ function Review residual toxicities: EV (neuropathy, rash), IO (immune-related AEs) Assess disease burden and sites (visceral/liver?) Review patient goals and preferences
      • IS THERE RAPID PROGRESSION OR VISCERAL CRISIS?
        E.g., symptomatic progression, liver metastases, organ compromise, rapid clinical decline.
        • YES: High-risk disease / rapid progression
          Consider urgent systemic therapy with high likelihood of response If eligible → platinum-based chemotherapy (prefer cisplatin if fit) Clinical trial if immediately available Palliative / local interventions as needed
        • NO: PRIOR PLATINUM EXPOSURE?
          • No prior platinum for metastatic disease
            • ASSESS PLATINUM ELIGIBILITY NOW
              • Cisplatin-eligible
                CrCl ≥ 60 mL/min ECOG 0–1 No grade ≥2 neuropathy or significant hearing loss No NYHA class III/IV heart failure
                • Gemcitabine + CISPLATIN (4–6 cycles)
                  • Assess response and tolerability
                    • Continue until progression or unacceptable toxicity
                      • TOXICITY-DRIVEN MODIFICATION
                        Residual EV-related neuropathy Grade ≥2 or function-limiting Avoid cisplatin Consider carboplatin or non-neuropathy-worsening strategies Optimize supportive care Prior immune-related toxicity Severe irAEs or steroid-dependent Avoid further IO rechallenge outside clinical trial Manage endocrine or organ toxicities
                        • PATIENT AND PRACTICE FACTORS
                          ECOG/PS, frailty, organ function Access to drugs and testing (FGFR, HER2) Clinical trial availability Logistics and financial toxicity Patient goals and preferences
                          • FINAL TREATMENT DECISION
                            Select the best option balancing: Expected benefit Urgency of disease control Toxicity risk Patient goals and quality of life Access and feasibility Clinical trial should be considered early whenever possible.
              • Cisplatin-ineligible but platinum-eligible
                CrCl 30–59 mL/min ECOG 0–2 Grade 0–1 neuropathy No prohibitive comorbidities
                • Gemcitabine + CARBOPLATIN (4–6 cycles)
                  • Assess response and tolerability
                    • Continue until progression or unacceptable toxicity
                      • TOXICITY-DRIVEN MODIFICATION
                        Residual EV-related neuropathy Grade ≥2 or function-limiting Avoid cisplatin Consider carboplatin or non-neuropathy-worsening strategies Optimize supportive care Prior immune-related toxicity Severe irAEs or steroid-dependent Avoid further IO rechallenge outside clinical trial Manage endocrine or organ toxicities
                        • PATIENT AND PRACTICE FACTORS
                          ECOG/PS, frailty, organ function Access to drugs and testing (FGFR, HER2) Clinical trial availability Logistics and financial toxicity Patient goals and preferences
                          • FINAL TREATMENT DECISION
                            Select the best option balancing: Expected benefit Urgency of disease control Toxicity risk Patient goals and quality of life Access and feasibility Clinical trial should be considered early whenever possible.
              • Platinum-ineligible
                CrCl < 30 mL/min ECOG ≥ 3 Severe comorbidities or frailty Poor marrow reserve
                • BIOMARKER AND PATIENT-CENTERED OPTIONS
                  • FGFR2/3 alteration present
                    FGFR inhibitor (erdafitinib or futibatinib) if available
                    • Reassess goals, comorbidities, toxicities and patient preference
                      • PATIENT AND PRACTICE FACTORS
                        ECOG/PS, frailty, organ function Access to drugs and testing (FGFR, HER2) Clinical trial availability Logistics and financial toxicity Patient goals and preferences
                        • FINAL TREATMENT DECISION
                          Select the best option balancing: Expected benefit Urgency of disease control Toxicity risk Patient goals and quality of life Access and feasibility Clinical trial should be considered early whenever possible.
                  • HER2 positive / HER2 altered
                    Clinical trial or HER2-directed therapy if available (enfortumab deruxtecan, trastuzumab deruxtecan, or other)
                    • Reassess goals, comorbidities, toxicities and patient preference
                      • PATIENT AND PRACTICE FACTORS
                        ECOG/PS, frailty, organ function Access to drugs and testing (FGFR, HER2) Clinical trial availability Logistics and financial toxicity Patient goals and preferences
                        • FINAL TREATMENT DECISION
                          Select the best option balancing: Expected benefit Urgency of disease control Toxicity risk Patient goals and quality of life Access and feasibility Clinical trial should be considered early whenever possible.
                  • No actionable biomarker or unknown
                    Clinical trial preferred Other systemic therapy or best supportive care
                    • Reassess goals, comorbidities, toxicities and patient preference
                      • PATIENT AND PRACTICE FACTORS
                        ECOG/PS, frailty, organ function Access to drugs and testing (FGFR, HER2) Clinical trial availability Logistics and financial toxicity Patient goals and preferences
                        • FINAL TREATMENT DECISION
                          Select the best option balancing: Expected benefit Urgency of disease control Toxicity risk Patient goals and quality of life Access and feasibility Clinical trial should be considered early whenever possible.
          • Prior perioperative platinum (neoadjuvant/adjuvant)
            • Long DFI* and good tolerance
              *DFI - disease-free interval (e.g., ≥12 months vs <12 months).
              • Consider platinum rechallenge if eligible
                • BIOMARKER AND PATIENT-CENTERED OPTIONS
                  • FGFR2/3 alteration present
                    FGFR inhibitor (erdafitinib or futibatinib) if available
                    • Reassess goals, comorbidities, toxicities and patient preference
                      • PATIENT AND PRACTICE FACTORS
                        ECOG/PS, frailty, organ function Access to drugs and testing (FGFR, HER2) Clinical trial availability Logistics and financial toxicity Patient goals and preferences
                        • FINAL TREATMENT DECISION
                          Select the best option balancing: Expected benefit Urgency of disease control Toxicity risk Patient goals and quality of life Access and feasibility Clinical trial should be considered early whenever possible.
                  • HER2 positive / HER2 altered
                    Clinical trial or HER2-directed therapy if available (enfortumab deruxtecan, trastuzumab deruxtecan, or other)
                    • Reassess goals, comorbidities, toxicities and patient preference
                      • PATIENT AND PRACTICE FACTORS
                        ECOG/PS, frailty, organ function Access to drugs and testing (FGFR, HER2) Clinical trial availability Logistics and financial toxicity Patient goals and preferences
                        • FINAL TREATMENT DECISION
                          Select the best option balancing: Expected benefit Urgency of disease control Toxicity risk Patient goals and quality of life Access and feasibility Clinical trial should be considered early whenever possible.
                  • No actionable biomarker or unknown
                    Clinical trial preferred Other systemic therapy or best supportive care
                    • Reassess goals, comorbidities, toxicities and patient preference
                      • PATIENT AND PRACTICE FACTORS
                        ECOG/PS, frailty, organ function Access to drugs and testing (FGFR, HER2) Clinical trial availability Logistics and financial toxicity Patient goals and preferences
                        • FINAL TREATMENT DECISION
                          Select the best option balancing: Expected benefit Urgency of disease control Toxicity risk Patient goals and quality of life Access and feasibility Clinical trial should be considered early whenever possible.
            • Short DFI* or poor tolerance
              *DFI - disease-free interval (e.g., ≥12 months vs <12 months).
              • Consider non-platinum options
                • BIOMARKER AND PATIENT-CENTERED OPTIONS
                  • FGFR2/3 alteration present
                    FGFR inhibitor (erdafitinib or futibatinib) if available
                    • Reassess goals, comorbidities, toxicities and patient preference
                      • PATIENT AND PRACTICE FACTORS
                        ECOG/PS, frailty, organ function Access to drugs and testing (FGFR, HER2) Clinical trial availability Logistics and financial toxicity Patient goals and preferences
                        • FINAL TREATMENT DECISION
                          Select the best option balancing: Expected benefit Urgency of disease control Toxicity risk Patient goals and quality of life Access and feasibility Clinical trial should be considered early whenever possible.
                  • HER2 positive / HER2 altered
                    Clinical trial or HER2-directed therapy if available (enfortumab deruxtecan, trastuzumab deruxtecan, or other)
                    • Reassess goals, comorbidities, toxicities and patient preference
                      • PATIENT AND PRACTICE FACTORS
                        ECOG/PS, frailty, organ function Access to drugs and testing (FGFR, HER2) Clinical trial availability Logistics and financial toxicity Patient goals and preferences
                        • FINAL TREATMENT DECISION
                          Select the best option balancing: Expected benefit Urgency of disease control Toxicity risk Patient goals and quality of life Access and feasibility Clinical trial should be considered early whenever possible.
                  • No actionable biomarker or unknown
                    Clinical trial preferred Other systemic therapy or best supportive care
                    • Reassess goals, comorbidities, toxicities and patient preference
                      • PATIENT AND PRACTICE FACTORS
                        ECOG/PS, frailty, organ function Access to drugs and testing (FGFR, HER2) Clinical trial availability Logistics and financial toxicity Patient goals and preferences
                        • FINAL TREATMENT DECISION
                          Select the best option balancing: Expected benefit Urgency of disease control Toxicity risk Patient goals and quality of life Access and feasibility Clinical trial should be considered early whenever possible.
          • Prior platinum for metastatic disease
            • BIOMARKER AND PATIENT-CENTERED OPTIONS
              • FGFR2/3 alteration present
                FGFR inhibitor (erdafitinib or futibatinib) if available
                • Reassess goals, comorbidities, toxicities and patient preference
                  • PATIENT AND PRACTICE FACTORS
                    ECOG/PS, frailty, organ function Access to drugs and testing (FGFR, HER2) Clinical trial availability Logistics and financial toxicity Patient goals and preferences
                    • FINAL TREATMENT DECISION
                      Select the best option balancing: Expected benefit Urgency of disease control Toxicity risk Patient goals and quality of life Access and feasibility Clinical trial should be considered early whenever possible.
              • HER2 positive / HER2 altered
                Clinical trial or HER2-directed therapy if available (enfortumab deruxtecan, trastuzumab deruxtecan, or other)
                • Reassess goals, comorbidities, toxicities and patient preference
                  • PATIENT AND PRACTICE FACTORS
                    ECOG/PS, frailty, organ function Access to drugs and testing (FGFR, HER2) Clinical trial availability Logistics and financial toxicity Patient goals and preferences
                    • FINAL TREATMENT DECISION
                      Select the best option balancing: Expected benefit Urgency of disease control Toxicity risk Patient goals and quality of life Access and feasibility Clinical trial should be considered early whenever possible.
              • No actionable biomarker or unknown
                Clinical trial preferred Other systemic therapy or best supportive care
                • Reassess goals, comorbidities, toxicities and patient preference
                  • PATIENT AND PRACTICE FACTORS
                    ECOG/PS, frailty, organ function Access to drugs and testing (FGFR, HER2) Clinical trial availability Logistics and financial toxicity Patient goals and preferences
                    • FINAL TREATMENT DECISION
                      Select the best option balancing: Expected benefit Urgency of disease control Toxicity risk Patient goals and quality of life Access and feasibility Clinical trial should be considered early whenever possible.
  2. CLINICAL TRIALS
    A key option at multiple points in the pathway, especially for patients who are platinum-ineligible, FGFR/HER2-negative, post-platinum, rapidly progressing, or have limited standard treatment options.
tosprivacyNCCN Bladder Cancer guidelinesESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinomaEAU Muscle-invasive and Metastatic Bladder Cancer guidelinesEnfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial CancerEnfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trialNivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial CarcinomaEfficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic DiseaseTreatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumabTreatment patterns and clinical outcomes with platinum-based chemotherapy after enfortumab vedotin and pembrolizumab in patients with metastatic urothelial carcinoma.Treatment Sequencing in Advanced Urothelial CancerUnresolved questions in the sequencing of systemic therapy for advanced urothelial carcinomaErdafitinib or Chemotherapy in Advanced or Metastatic Urothelial CarcinomaFDA approves erdafitinib for locally advanced or metastatic urothelial carcinomaFDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumorsTrastuzumab deruxtecan (T-DXd) in pretreated patients (pts) with HER2-expressing bladder cancer: Final results from the bladder cancer cohort in Part 1 of DESTINY-PanTumor02 (DP-02).FDA grants accelerated approval to sacituzumab govitecan for advanced urothelial cancerTherapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape